PMID- 11587369
OWN - NLM
STAT- MEDLINE
DCOM- 20011011
LR  - 20190901
IS  - 0344-5704 (Print)
IS  - 0344-5704 (Linking)
VI  - 48 Suppl 1
DP  - 2001 Aug
TI  - Multicenter prospective study of interferon-alpha versus bone marrow 
      transplantation for newly diagnosed patients with chronic myelogenous leukemia: a 
      preliminary analysis.
PG  - S59-64
AB  - Interferon-alpha (IFN-alpha) therapy was compared with bone marrow 
      transplantation (BMT) in patients with chronic myelogenous leukemia (CML) in a 
      multicenter, prospective study. Of 254 evaluable patients, 175 received IFN-alpha 
      and 79 received allogeneic BMT, 50 of whom received transplants from human 
      leukocyte antigen (HLA)-identical related donors and 29 from HLA-matched 
      unrelated donors. Complete hematologic response was achieved by 148 patients 
      (89%) in the IFN-alpha group and 53 (78%) in the BMT group. In the IFN-alpha 
      group, a complete cytogenetic response was induced in 25 patients (15%), a 
      partial cytogenetic response in 37 (23%), and a minor cytogenetic response in 41 
      (25%). At a median follow-up of 38 months, in the IFN-alpha group the predicted 
      5-year survival rate was 79%, and the predicted 5-year rate of remaining in 
      chronic phase was 66%. In the BMT group the predicted 5-year survival rate was 
      72% for related-donor BMT and 67% for unrelated-donor BMT. Among low Sokal-risk 
      patients, 5-year survival did not differ between IFN-alpha therapy and BMT, 
      irrespective of age. In higher Sokal-risk patients, survival for related-donor 
      BMT and unrelated-donor BMT tended to be better than that with IFN-alpha therapy 
      in younger patients. On the other hand, in older patients, survival in the BMT 
      group, especially for those receiving unrelated-donor BMT, appeared to be 
      inferior to that in the IFN-alpha group. Unrelated-donor BMT can be recommended 
      for high-risk younger patients. However, for older patients, it should be 
      performed after careful consideration of prognostic factors such as age, Sokal 
      score, and response to IFN-alpha.
FAU - Ohnishi, K
AU  - Ohnishi K
AD  - Department of Medicine III, Hamamatsu University School of Medicine, Handayama, 
      Japan. kohnishi@hama-med.ac.jp
FAU - Ino, T
AU  - Ino T
FAU - Kishimoto, Y
AU  - Kishimoto Y
FAU - Usui, N
AU  - Usui N
FAU - Shimazaki, C
AU  - Shimazaki C
FAU - Ohtake, S
AU  - Ohtake S
FAU - Taguchi, H
AU  - Taguchi H
FAU - Kusumoto, S
AU  - Kusumoto S
FAU - Kuriyama, K
AU  - Kuriyama K
FAU - Hotta, T
AU  - Hotta T
FAU - Ohno, R
AU  - Ohno R
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interferon-alpha)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Bone Marrow Transplantation
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hydroxyurea/administration & dosage
MH  - Interferon-alpha/administration & dosage/*therapeutic use
MH  - Leukemia, Myeloid, Chronic-Phase/*drug therapy/*therapy
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Survival Rate
EDAT- 2001/10/06 10:00
MHDA- 2001/10/12 10:01
CRDT- 2001/10/06 10:00
PHST- 2001/10/06 10:00 [pubmed]
PHST- 2001/10/12 10:01 [medline]
PHST- 2001/10/06 10:00 [entrez]
AID - 10.1007/s002800100307 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S59-64. doi: 
      10.1007/s002800100307.